← Back to Search

Monoclonal Antibodies

LY3041658 for Hidradenitis Suppurativa

Phase 2
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 16

Summary

This trial is testing if the drug LY3041658 can help people with moderate-to-severe hidradenitis suppurativa by reducing inflammation and preventing painful lumps.

Eligible Conditions
  • Hidradenitis Suppurativa

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 16
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 16 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16
Secondary study objectives
Mean Change From Baseline to Week 16 in Skin Pain on the HS Numeric Rating Scale (NRS)
Mean Change From Baseline to Week 16 in Total Number of Abscesses and Inflammatory Nodules (AN) Count

Side effects data

From 2022 Phase 2 trial • 72 Patients • NCT04493502
10%
Covid-19
8%
Nasopharyngitis
6%
Upper respiratory tract infection
4%
Arthralgia
2%
Pneumonia
2%
Atrial fibrillation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo_Double-Blind Treatment Period
600 mg LY3041658_Open-Label Extension
Follow-Up Period
600 mg LY3041658 _Double-Blind Treatment Period

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3041658Experimental Treatment1 Intervention
Participants received 600 mg LY3041658 administered intravenously (IV) once every 2 weeks (Q2W).
Group II: PlaceboPlacebo Group2 Interventions
Placebo administered IV. Participants will switch to 600 mg LY3041658 administered IV after week 16.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3041658
2020
Completed Phase 2
~150

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,675 Previous Clinical Trials
3,463,911 Total Patients Enrolled
1 Trials studying Hidradenitis Suppurativa
350 Patients Enrolled for Hidradenitis Suppurativa
Study DirectorEli Lilly and Company
1,388 Previous Clinical Trials
427,306 Total Patients Enrolled
1 Trials studying Hidradenitis Suppurativa
350 Patients Enrolled for Hidradenitis Suppurativa
~14 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top